- Paxlovid didn’t shorten Covid symptoms in vaccinated adults, full trial results confirm Endpoints News
- Among fully vaccinated, study shows Paxlovid does not shorten symptoms University of Minnesota Twin Cities
- Paxlovid Fails to Shorten COVID in Standard-Risk and Vaccinated At-Risk Patients Medpage Today
- Predictors of nirmatrelvir–ritonavir receipt among COVID-19 patients in a large US health system | Scientific Reports Nature.com
- Paxlovid is effective against Covid-19, but many people eligible for it are not getting it; it’s fre … The Lexington Times
Tag Archives: Endpoints
Merck details PhII TIGIT/PD-1 fail in lung cancer – Endpoints News
- Merck details PhII TIGIT/PD-1 fail in lung cancer Endpoints News
- Merck stock falls as cancer trial for Keytruda combo fails Seeking Alpha
- Merck’s lung cancer drug combo fails trial in setback for new therapy class Reuters
- Merck & Co. digs into TIGIT fail, sharing survival data from phase 2 lung cancer trial FierceBiotech
- Merck Announces Findings from Phase 2 KeyVibe-002 Trial Evaluating an Investigational Coformulation of Vibostolimab and Pembrolizumab in Previously Treated Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) Business Wire
Bristol Myers and 2seventy bio say FDA delayed CAR-T therapy decision – Endpoints News
- Bristol Myers and 2seventy bio say FDA delayed CAR-T therapy decision Endpoints News
- Bristol Myers Squibb (NYSE:BMY) Falls after FDA Delays Action on Cancer Therapy – TipRanks.com TipRanks
- Bristol Myers Squibb and 2seventy bio Provide Update on U.S. FDA Review of sBLA for Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma Bristol-Myers Squibb
- Why Is Pharma Giant Bristol-Myers Squibb (BMY) Stock Trading Lower Today? – 2seventy bio (NASDAQ:TSVT), B Benzinga
- View Full Coverage on Google News
FDA approves Junshi, Coherus’ PD-1 toripalimab for nasopharyngeal carcinoma – Endpoints News
- FDA approves Junshi, Coherus’ PD-1 toripalimab for nasopharyngeal carcinoma Endpoints News
- Coherus rejects ‘heavily discounted’ pricing on Loqtorzi, the first China-made PD-1 drug to win FDA nod FiercePharma
- FDA Approves Loqtorz Regimens for Advanced Nasopharyngeal Carcinoma Curetoday.com
- Coherus and Junshi Biosciences Announce FDA Approval of LOQTORZI™ (toripalimab-tpzi) in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) Yahoo Finance
- Peninsula drug maker Coherus wins FDA cancer drug approval, extends one lease, exits other space – San Francisco Business Times The Business Journals
- View Full Coverage on Google News
Sanofi’s atopic dermatitis drug amlitelimab hits primary endpoint, on its way to PhIII trial – Endpoints News
- Sanofi’s atopic dermatitis drug amlitelimab hits primary endpoint, on its way to PhIII trial Endpoints News
- Press Release: Late-breaking amlitelimab Phase 2b data presented at EADV show potential best-in-class profile in atopic dermatitis Yahoo Finance
- Sanofi reaps rewards of immunology investment with eczema results MarketWatch
- ASLAN Pharmaceuticals Presents New Data From Phase 2b Study of Eblasakimab in Atopic Dermatitis in Late Breaker Presentation at 32nd European Academy of Dermatology and Venereology Congress GlobeNewswire
- Amlitelimab A Revolutionary Solution for Atopic Dermatitis Best Stocks
- View Full Coverage on Google News
Novo Nordisk snaps up Inversago Pharma for up to $1B+ on the back of megablockbuster Wegovy sales – Endpoints News
- Novo Nordisk snaps up Inversago Pharma for up to $1B+ on the back of megablockbuster Wegovy sales Endpoints News
- Novo Nordisk to acquire obesity drug developer Inversago Reuters
- Novo Nordisk bets $1.1B on Canadian biotech buyout, adding an old approach to obesity pipeline FierceBiotech
- Novo Nordisk to acquire Inversago Pharma to develop new therapies for people living with obesity, diabetes and other serious metabolic diseases GlobeNewswire
- Novo acquires Inversago for up to $1 billion, spotlighting troubled weight loss approach STAT
- View Full Coverage on Google News
Sage suggests job and pipeline cuts after FDA rejection of major depression pill – Endpoints News
- Sage suggests job and pipeline cuts after FDA rejection of major depression pill Endpoints News
- Sage Therapeutics stock plunges more than 50% after FDA denies wider use of postpartum depression drug CNBC
- Sage Therapeutics’ stock drops 49% after FDA approves zuranolone for postpartum depression but not for major depressive disorder MarketWatch
- Why Sage Therapeutics Shares Are Sinking Monday – Sage Therapeutics (NASDAQ:SAGE) Benzinga
- Sage Therapeutics Announces Second Quarter 2023 Financial Results and Highlights Pipeline and Business Progress Yahoo Finance
- View Full Coverage on Google News
Updated: EQRx sells itself to another Alexis Borisy company, Revolution Medicines, in all-stock deal – Endpoints News
- Updated: EQRx sells itself to another Alexis Borisy company, Revolution Medicines, in all-stock deal Endpoints News
- Revolution Medicines, Inc. to Acquire EQRx, Inc. in All-Stock Transaction to Gain More Than $1 Billion in Additional Capital GlobeNewswire
- EQRx’s low cost drug dream ends in Revolution FierceBiotech
- Revolution Medicines to acquire EQRx in deal that will add $1 billion in cash to its balance sheet to fund R&D MarketWatch
- Revolution Medicines To Acquire EQRx In All-Stock Transaction To Gain Over $1B In Additional Capital – EQ Benzinga
- View Full Coverage on Google News
AstraZeneca dives into regulatory T cell therapies in deal with Quell Therapeutics – Endpoints News
- AstraZeneca dives into regulatory T cell therapies in deal with Quell Therapeutics Endpoints News
- AstraZeneca pays $85M to Quell Type 1 diabetes with ‘one and done’ cell therapy FierceBiotech
- AstraZeneca signs $2 billion agreement with Quell to develop cell therapies Reuters
- Quell Therapeutics Signs a Collaboration, Exclusive Option and License Agreement with AstraZeneca to Develop, Manufacture and Commercialize Engineered Treg Cell Therapies for Autoimmune Diseases GlobeNewswire
- Astra Enters Into $2 Billion-Plus Pact With UK Biotech Quell Bloomberg
- View Full Coverage on Google News
Moderna, Merck say their cancer vaccine reduces metastases by 65% in PhII study of high-risk melanoma: #ASCO23 – Endpoints News
- Moderna, Merck say their cancer vaccine reduces metastases by 65% in PhII study of high-risk melanoma: #ASCO23 Endpoints News
- Moderna and Merck cancer vaccine used with Keytruda reduces risk of deadly skin cancer spreading CNBC
- Cancer vaccines poised to unlock ‘new treatment paradigm’ with Merck/Moderna data KSL.com
- Moderna and Merck reveal new data on individualized cancer treatment MarketWatch
- Moderna and Merck Announce mRNA-4157 (V940) in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Yahoo Finance
- View Full Coverage on Google News